Stocks making the biggest moves in the premarket: Horizon Therapeutics, Coupa Software, Rivian and more

Australia News News

Stocks making the biggest moves in the premarket: Horizon Therapeutics, Coupa Software, Rivian and more
Australia Latest News,Australia Headlines
  • 📰 CNBC
  • ⏱ Reading Time:
  • 21 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 72%

The stocks making the biggest moves in premarket trading include Horizon Therapeutics, Coupa Software, Rivian, and more.

– Goldman Sachs upgraded Gap and Tapestry to "buy" from "neutral" while downgraded Levi Strauss to "neutral" from "buy." Goldman said its moves were based on which companies can thrive in an atmosphere that will see consumers become more discerning with their apparel spending. Gap added 2.

7% in the premarket, with Tapestry up 2% and Levi Strauss losing 1.2%. – The restaurant operator's stock slid 3.7% after Goldman downgraded it to "sell" from "neutral." Goldman said it was cautiously optimistic about the long-term results of the company's effort to turn around its Chili's chain, but thinks 2023 will be choppy in terms of sales and profit margins.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

CNBC /  🏆 12. in US

Australia Latest News, Australia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

WSJ News Exclusive | Amgen in Advanced Talks to Buy Horizon TherapeuticsWSJ News Exclusive | Amgen in Advanced Talks to Buy Horizon TherapeuticsAmgen is in advanced talks to buy drugmaker Horizon Therapeutics, people familiar with the matter say, in a deal likely to be valued at well over $20 billion
Read more »

Amgen reportedly in talks to buy Horizon TherapeuticsAmgen reportedly in talks to buy Horizon TherapeuticsThe U.S. biotechnology company AMGN was the last of three suitors standing in an auction for Horizon, according to sources cited by The Wall Street Journal.
Read more »

Amgen confirms to acquire Horizon Therapeutics in cash deal valued at about $27.8 billionAmgen confirms to acquire Horizon Therapeutics in cash deal valued at about $27.8 billionAmgen Inc. undefined said Monday it has agreed to acquire Horizon Therapeutics Plc undefined in an all-cash deal valued at $27.8 billion, confirming earlier...
Read more »

Amgen Agrees to Deal to Buy Horizon TherapeuticsAmgen Agrees to Deal to Buy Horizon TherapeuticsThe U.S. biotech company agreed to buy drugmaker Horizon Therapeutics in a deal valued at $27.8 billion, marking the largest healthcare merger of the year.
Read more »

Amgen set to buy biotech firm Horizon at $26 bln valuation - Bloomberg NewsAmgen set to buy biotech firm Horizon at $26 bln valuation - Bloomberg NewsAmgen Inc is set to buy biotech firm Horizon Therapeutics Plc at a valuation of about $26 billion in what would be its largest acquisition, Bloomberg News reported on Monday.
Read more »

Amgen emerges frontrunner in Horizon deal as Sanofi drops bidAmgen emerges frontrunner in Horizon deal as Sanofi drops bidAmgen Inc is in advanced talks to buy biotech company Horizon Therapeutics Plc , the Wall Street Journal reported on Sunday, while rival bidder French health group Sanofi announced it had dropped its bid.
Read more »



Render Time: 2025-02-28 09:47:16